SIGLEC9 (CN 111465614 A Biosimilar) Recombinant Monoclonal Antibody

說明書

貨號：

CSB-RA021303MB1HU
規(guī)格：
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

Q9Y336
基因名：

SIGLEC9
別名：

CD329 antibody; CDw329 antibody; FOAP 9 antibody; OB binding protein like antibody; OBBP LIKE antibody; Protein FOAP 9 antibody; Protein FOAP-9 antibody; sialic acid binding Ig like lectin 9 antibody; Sialic acid-binding Ig-like lectin 9 antibody; Sialic acid-binding immunoglobulin like lectin 9 antibody; SIGL9_HUMAN antibody; Siglec 9 antibody; Siglec-9 antibody; SIGLEC9 antibody
反應(yīng)種屬：

Human
免疫原：

Recombinant Human SIGLEC9 protein
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.151
產(chǎn)品提供形式：

Liquid
應(yīng)用說明：

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

In stock
用途：

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- or alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.
基因功能參考文獻(xiàn)：
1. The SIGLEC9 rs2075803 G/rs2258983 A haplotype, which corresponds to a Siglec-9 variant that is less effective at suppressing inflammatory response, may be a risk factor for the development of emphysema. PMID: 27878892
2. Glycophorin A, the most abundant sialoglycoprotein on erythrocytes, engaged neutrophil Siglec-9, a sialic acid-recognizing receptor known to dampen innate immune cell activation. These studies demonstrate a previously unsuspected role for erythrocytes in suppressing neutrophils ex vivo and in vitro and help explain why neutrophils become easily activated after separation from whole blood. PMID: 28416510
3. Data suggest that sialic acid-binding Ig-like lectin-9 (Siglec-9)may serve as a potential diagnostic and therapeutic target for rheumatoid arthritis (RA). PMID: 28273363
4. The mechanism of the Siglec-9 and AOC3 interaction is mediated both by protein-sugar interactions via the V domain and by the protein-protein interactions via the C22 Siglec9 domain. PMID: 27893774
5. This work defines a critical role for aberrantly glycosylated MUC1 and identifies an activating pathway that follows engagement of Siglec-9. PMID: 27595232
6. Constitutively expressed Siglec-9 inhibits LPS-induced CCR7, but enhances IL-4-induced CD200R expression in human macrophages. PMID: 26923638
7. Ligands for Siglec-8 and Siglec-9 may regulate the function of eosinophils, mast cells, neutrophils, and other cells in sinus mucosa. PMID: 26694037
8. Inflammation results in up-regulation of immuneinhibitory Siglec-8 and Siglec-9 sialoglycan ligands on human airways. PMID: 25747723
9. a polymorphism that reduced Siglec-9 binding to carcinomas was associated with improved early survival in non-small-cell lung cancer patients PMID: 25225409
10. Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3. PMID: 24882272
11. Protein degradation of focal adhesion kinase and related molecules was induced by Siglec-9 binding to its counterreceptors via sialylglycoconjugates, leading to the modulation of adhesion kinetics of cancer cells. PMID: 24145038
12. Siglec-9 expressed on immune cells may play a role as a potential counterreceptor for MUC1 and that this signaling may be another MUC1-mediated pathway and function in parallel with a growth factor-dependent pathway. PMID: 24045940
13. The Siglec-9 peptide binding to the enzymatic groove of VAP-1 can be used for imaging conditions, such as inflammation and cancer. PMID: 21821708
14. Siglec-9 A391C was the only polymorphism related to TCR-mediated signaling in human Siglec-9, resulting in less inhibition compared to the wild type. PMID: 20733319
15. These results suggest that Siglec-9 expressed on DCs is involved in immunoregulation through ligation with mucins in an epithelial cancer patient. PMID: 20971061
16. MUC16-Siglec-9 binding likely mediates inhibition of anti-tumor immune responses. PMID: 20497550
17. Septic shock patients exhibit different ex vivo death responses of blood neutrophils after Siglec-9 ligation early in shock. PMID: 19295491
18. Binding studies on recombinant human Siglec-9 show recognition of both Neu5Ac and Neu5Gc; in striking contrast, chimpanzee and gorilla Siglec-9 strongly prefer binding Neu5Gc. PMID: 14693915
19. Siglec-9 can inhibit Fc epsilon receptor I-mediated serotonin release from rat basophilic leukemia cells and recruit the tyrosine phosphatases SHP-1 and SHP-2. PMID: 15557178
20. data suggest that apoptotic (ROS- and caspase-dependent) and nonapoptotic (ROS-dependent) death pathways are initiated in neutrophils via Siglec-9 PMID: 15827126
21. Siglecs-9 did not interact with sulfate derivatives of LacNAc and sulfated oligosaccharides containing sialic acid. PMID: 16732727
22. The Siglec-9 provides not only a useful marker for certain subsets of AML, but also a potential therapeutic target. PMID: 16828866
23. These results demonstrate that Siglec-9 enhances the production of the anti-inflammatory cytokine IL-10 in macrophages. PMID: 18325328
24. A review of the cytotoxic effects of natural anti-Siglec9 autoantibodies on both neutrophils and eosinophils. PMID: 18558361
25. Increased bacterial survival are also facilitated by group b Streptococcus sialylated capsular polysaccharide interactions with Siglec-9. PMID: 19196661
26. Data suggest that age-specific interactions between Siglec-9 and SHP-1 may influence the altered inflammatory responsiveness and longevity of neonatal polymorphonuclear neutrophils. PMID: 19542910
顯示更多

收起更多
亞細(xì)胞定位：

Membrane; Single-pass type I membrane protein.
蛋白家族：

Immunoglobulin superfamily, SIGLEC (sialic acid binding Ig-like lectin) family
組織特異性：

Expressed by peripheral blood leukocytes (neutrophils and monocytes but not eosinophils). Found in liver, fetal liver, bone marrow, placenta, spleen and in lower levels in skeletal muscle, fetal brain, stomach, lung, thymus, prostate, brain, mammary, adre
數(shù)據(jù)庫鏈接：

HGNC: 10878

OMIM: 605640

KEGG: hsa:27180

STRING: 9606.ENSP00000413861

UniGene: Hs.245828

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human